Senesco Technologies Inc. is planning to merge with Fabrus Inc.
Senesco, headquartered in Bridgewater, N.J., is a clinical-stage biotechnology company that specializes in cancer therapeutics. The company is currently developing a product that is designed to treat certain types of cancer, including multiple myeloma, lymphocytic leukemia and non-Hodgkin’s B-cell lymphomas.
La Jolla, Calif.-based Fabrus is also a biotechnology company that focuses on developing antibodies to treat multiple types of diseases. "Fabrus antibodies could complement our eIF5A gene regulatory platform, which has been shown to kill cancer cells, by directing nanoparticle-based therapeutics to the cells of interest," says Leslie Browne, CEO of Senesco.
The transaction follows deals between several companies that develop cancer medication. In October, Imugene agreed to buy Biolife Science Qld Ltd., which owns the rights to a cancer immunotherapy. In September, the Menarini Group bought Silicon Biosystems SpA, which develops technology to analyze tumor cells.